Ciltacabtagene autoleucel is under clinical development by Legend Biotech and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase III drugs for Multiple Myeloma (Kahler Disease) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ciltacabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ciltacabtagene autoleucel overview
Ciltacabtagene autoleucel (Carvykti) is a BCMA-directed genetically modified autologous T cell immunotherapy. It is formulated as suspension for intravenous route of administration. Carvykti is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Legend Biotech overview
Legend Biotech, a subsidiary of Genscript Biotech Corp, is a commercial-stage biotechnology company. It primarily focuses on the development, manufacturing, and commercialization of novel cell therapies. The company’s main focus is on diseases considered intractable and incurable, such as hematological malignancies and solid tumors. Its products candidate includes GPC3 for the treatment of non-small cell lung cancer (NSCLC), tumors and others. Legend Biotech‘s therapies are designed for patients worldwide suffering from chronic and life-threatening diseases. The company operates in the Americas and Europe. Legend Biotech is headquartered in Somerset, New Jersey, the US.
For a complete picture of Ciltacabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
